Key Points
- Insider sale: Guardant Health insider Terilyn Monroe sold 55,167 shares at an average price of $105.97 for about $5.85 million, reducing her holding to 20,920 shares (a 72.51% drop), as disclosed in an SEC filing.
- Recent results: Guardant reported Q EPS of ($0.39) versus a ($0.48) consensus and delivered revenue growth of 38.5% year-over-year, beating expectations on the bottom line.
- Market and analyst picture: The stock trades near $106 (12‑month range $29.91–$112.43) with a market cap around $13.36 billion and negative P/E; analysts’ consensus is a Moderate Buy (23 Buys, 1 Sell) with an average target of $80.86.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 55,167 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $105.97, for a total value of $5,846,046.99. Following the transaction, the insider directly owned 20,920 shares in the company, valued at approximately $2,216,892.40. This represents a 72.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Guardant Health Stock Performance
GH opened at $105.96 on Thursday. The business has a 50 day moving average price of $82.86 and a 200 day moving average price of $62.34. Guardant Health, Inc. has a twelve month low of $29.91 and a twelve month high of $112.43. The firm has a market cap of $13.36 billion, a P/E ratio of -33.01 and a beta of 1.58.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same period last year, the company posted ($0.88) EPS. Guardant Health's revenue for the quarter was up 38.5% compared to the same quarter last year. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Guardant Health
Large investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC lifted its position in Guardant Health by 37.3% in the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company's stock worth $2,564,000 after purchasing an additional 16,363 shares during the period. Yorktown Management & Research Co Inc bought a new stake in Guardant Health in the 2nd quarter valued at $289,000. Osterweis Capital Management Inc. acquired a new position in shares of Guardant Health in the 1st quarter valued at $12,634,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Guardant Health by 6.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,236 shares of the company's stock worth $3,035,000 after acquiring an additional 4,056 shares during the period. Finally, Strs Ohio bought a new position in shares of Guardant Health during the 1st quarter worth about $809,000. Institutional investors and hedge funds own 92.60% of the company's stock.
Analysts Set New Price Targets
Several research analysts recently commented on the stock. Citigroup lifted their target price on shares of Guardant Health from $65.00 to $100.00 and gave the stock a "buy" rating in a report on Thursday, October 30th. Stifel Nicolaus set a $73.00 price target on Guardant Health in a research report on Thursday, September 25th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $60.00 to $70.00 and gave the stock an "overweight" rating in a research report on Thursday, September 25th. Wolfe Research upgraded Guardant Health from a "peer perform" rating to an "outperform" rating and set a $75.00 target price for the company in a research note on Thursday, September 25th. Finally, Mizuho set a $100.00 price target on Guardant Health in a research report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $80.86.
Check Out Our Latest Report on Guardant Health
About Guardant Health
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
